Cik daudz dividendes maksā Richter Gedeon Vegyeszeti Gyar Nyrt 2024?
Saskaņā ar aktuālo informāciju no novembris 2024, Richter Gedeon Vegyeszeti Gyar Nyrt pēdējo 12 mēnešu laikā izmaksāja kopējo dividendes summu 391,32 HUF pro akciju. Pie pašreizējā Richter Gedeon Vegyeszeti Gyar Nyrt kursa 10 680,00 HUF, tas atbilst dividendes ienesīgumam 3,66 %.
Dividendes tiek izmaksātas reizes gadā.
3,66 % Dividends rendite | = | 391,32 HUF Dividende | 10 680,00 HUF akciju cena |
|
Vai Richter Gedeon Vegyeszeti Gyar Nyrt dividende ir droša?
Richter Gedeon Vegyeszeti Gyar Nyrt palielina dividendes jau 1 gadus.
Pēdējo 10 gadu laikā Richter Gedeon Vegyeszeti Gyar Nyrt ir paaugstināts to par 19,481 % gadā.
Pēdējo piecu gadu laikā izmaksas palielinājās par 41,896 %.
Analisti prognozē, ka šajā tekošajā finanšu gadā gaidāms Dividendu pieaugums aptuveni 5,748%.
Richter Gedeon Vegyeszeti Gyar Nyrt Aktienanalyse
Ko dara Richter Gedeon Vegyeszeti Gyar Nyrt?
Richter Gedeon Vegyeszeti Gyar Nyrt (Richter) is a company specialized in pharmaceutical and chemical products, with its headquarters in Budapest, Hungary. It was founded in 1901 by Gedeon Richter and has had a diverse history since then. In the 1920s, Richter began producing pharmaceuticals and became one of the leading pharmaceutical companies in Europe over the following decades. In the 1960s, the company made an important step with the introduction of the contraceptive "Anovlar," which was also a great success internationally.
Today, Richter is a globally operating company involved in various business fields. Its main divisions are pharmaceutical production, chemical manufacturing, and research and development of medications. In pharmaceutical production, Richter specializes in medicines for women's health, neurology, and pain medicine. Some of its well-known products include the painkiller "Novalgin," the hormone preparation "Divina," and the antidepressants "Cipralex" and "Lexapro." Richter also manufactures biosimilars and generics, making it an important player in the generic drug market.
Chemical manufacturing is another significant business area for Richter, producing intermediate products and fine chemicals used in various industries. This includes chemicals for the production of polymers, agrochemicals, and electronic components.
Research and development of medications are a central focus of Richter. The company operates several research facilities and maintains close relationships with academic institutions worldwide. Its goal is to discover and develop new active ingredients to treat medical conditions for which there are currently no or insufficient therapies.
Overall, Richter employs more than 12,000 people and operates in around 40 countries worldwide. It is listed on the Budapest Stock Exchange and is one of Hungary's largest publicly traded companies. In recent years, Richter has also focused on the Asian market and plans to further expand its activities in this region. In addition to the production of generics and chemicals, the company aims to distribute its own pharmaceuticals in China and other Asian countries.
In summary, Richter is a diversified company active in various fields, specializing primarily in the production of high-quality pharmaceuticals. With its long-standing experience, high quality standards, and broad product range, Richter is one of the key players in the pharmaceutical industry in Europe and worldwide. Richter Gedeon Vegyeszeti Gyar Nyrt ir viens no populārākajiem uzņēmumiem vietnē Eulerpool.com.Akcienu ieguldījumu plāni piedāvā investoriem pievilcīgu iespēju ilgtermiņā uzkrāt kapitālu. Viens no galvenajiem priekšrocībām ir tā sauktais Vidējās izmaksas efekts: ieguldot regulāri noteiktu summu akcijās vai akciju fondos, automātiski tiek iegādāts vairāk daļu, kad cenas ir zemas, un mazāk, kad tās ir augstas. Tas laika gaitā var novest pie izdevīgākas vidējās cenas par daļu. Turklāt akcienu ieguldījumu plāni nodrošina piekļuvi dārgām akcijām arī mazajiem investoriem, jo tiem var pievienoties jau ar nelielām summu. Regulāra ieguldījumu veikšana arī veicina disciplinētu ieguldījumu stratēģiju un palīdz izvairīties no emocionāliem lēmumiem, piemēram, impulsīvas pirkšanas vai pārdošanas. Turklāt investori gūst labumu no potenciālās akciju vērtības pieauguma un no dividendēm, kuras var reinvestēt, tādejādi pastiprinot procentu uz procentu efektu un līdz ar to investētā kapitāla augšanu.